This inventor holds 5 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Tohoku University, Zenoaq Resource Co., Ltd., Ono Pharmaceutical Co., Ltd.. Active years: 2019-2024.
Company Filing History:
4 out of 1,051 
3 out of 3 
1 out of 575 Years Active: 2019-2024
Title: Yukinari Kato: Innovator in Cancer Therapeutics
Introduction
Yukinari Kato is a prominent inventor based in Miyagi, Japan. He has made significant contributions to the field of cancer therapeutics, holding a total of 5 patents. His work focuses on developing targeted agents that can effectively combat cancer cells.
Latest Patents
Among his latest patents is a HER2 targeting agent. This invention discloses an antibody or antigen-binding fragment that binds to HER2 expressed on cancer cells. The patent also includes a pharmaceutical composition containing this HER2-targeting agent. Another notable patent is the anti-podoplanin antibody, which provides a cancer cell-specific antibody or antigen-binding fragment. This invention targets a specific epitope in a Thr85-containing region of the human podoplanin amino acid sequence.
Career Highlights
Yukinari Kato has worked with esteemed institutions such as Tohoku University and Zenoaq Resource Co., Ltd. His research has been pivotal in advancing cancer treatment methodologies. His innovative approaches have garnered attention in the scientific community.
Collaborations
Yukinari has collaborated with notable individuals in his field, including Mika Kato and Satoshi Ogasawara. These collaborations have further enriched his research and development efforts.
Conclusion
Yukinari Kato's contributions to cancer therapeutics through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for innovative treatments that can improve patient outcomes.